Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed Dosing in Platinum-Resistant Ovarian or Primary Peritoneal Cancer
2004-002784-24Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pemetrexed in ovarian cancer and primary peritoneal cancer (PPC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Tumor response rate. Started Mar 2005; status: completed.
02
Drugs
pemetrexed
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2004-002784-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002784-24.